Search

Now showing items 1-5 of 5

A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa.

MILLINGTON-WARD, SOPHIA; FARRAR, JANE (2013)

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

FARRAR, JANE; KENNA, PAUL; KIANG, ANNA-SOPHIA; HUMPHRIES, MARIAN; HUMPHRIES, PETER; TAM, LAWRENCE; CAMPBELL, MATTHEW (2010)

Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa

MILLINGTON-WARD, SOPHIA; O'REILLY, MARY; PALFI, ARPAD; KILTY, CLAIRE; HUMPHRIES, MARIAN; KENNA, PAUL; FARRAR, JANE; HUMPHRIES, PETER; CHADDERTON, NAOMI (2011)

CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression.

FARRAR, JANE (2013)

Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).

FARRAR, JANE; HUMPHRIES, MARIAN; HUMPHRIES, PETER; CAMPBELL, MATTHEW (2008)

Browse

All of TARA

This Academic/Research Unit

Discover

Author

Subject

Date Issued

Sponsor

Search

A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa.

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa

CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression.

Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).

Browse

All of TARA

This Academic/Research Unit

Discover

Author

Subject

Date Issued

Sponsor

Search

Advanced Search

A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa.

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa

CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression.

Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).